Abstract: Objective To investigate the ways in which EDTA-dependent pseudothrombocytopenia (EDTA-PTCP) is identified and differentiated during chemotherapy in order to provide a reference for quick clinical diagnosis. Methods The clinical data of one breast cancer patient who experienced a significant decrease in platelet count after treatment with liposomal paclitaxel was analyzed. By reviewing the patient’s medical history, medications, and laboratory test results, the association between EDTA-PTCP and liposomal paclitaxel was studied, and recommendations for re-testing with alternative anticoagulants were proposed. Results The pharmacist assessed the likelihood of EDTA-PTCP associated with paclitaxel liposome. After replacement of the anticoagulant and retesting, the patient’s platelet count returned to normal. The patient’s subsequent chemotherapy plan was not affected, and the condition was stable. Conclusion In case of thrombocytopenia during chemotherapy, the possibility of EDTA-PTCP should be considered. Peripheral blood smears or retesting with a different anticoagulant should be adopted to confirm the diagnosis.

Key words: Paclitaxel Liposome, Breast Cancer, EDTA, Chemotherapy-Induced Thrombocytopenia, Pseudothrom-bocytopenia, Adverse Drug Reaction, Chemotherapy